RNAi Therapeutic Vutrisiran for hATTR Amyloidosis has been approved by the FDA.

Published Date: 27 Apr 2023

When administered subcutaneously once every three months, vutrisiran, the first and only FDA-approved medication, has shown to reverse neuropathy impairment.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.

2.

Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.

3.

Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain

4.

Report suggests a big improvement in lung cancer survival

5.

The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot